Objective: To investigate the predictive value of serum lipoprotein (a) [Lp(a)] and high-sensitivity C-reactive protein/high-density lipoprotein ratio (CHR) for short-term prognosis in patients with acute myocardial infarction (AMI). Methods: A total of 251 patients with AMI who underwent percutaneous coronary intervention in the Department of Cardiology of Baotou Central Hospital from July 2021 to July 2022 were selected for retrospective analysis. The general data, laboratory indexes, killip classification, ejection fraction (EF value) and coronary angiography results of the enrolled patients were collected. The CHR value and Gensini score were calculated according to the laboratory indexes and coronary angiography results. According to whether major adverse cardiovascular events (MACE) occurred during hospitalization of AMI patients, they were divided into observation group and control group. The differences of general data and laboratory indexes between the two groups were compared. Univariate and multivariate logistic regression were used to analyze the influencing factors of MACE in AMI patients during hospitalization. The receiver operating characteristic (ROC) curve was used to analyze the predictive value of Lp(a), CHR and Lp(a) combined detection of CHR for MACE. Results: The Lp(a), CHR, killip grade≥II and Gensini score in the observation group were higher than those in the control group, and the differences were statistically significant (P＜0.05). Lp (a) and CHR were independent risk factors for MACE in patients with AMI during hospitalization. ROC curve showed that the combined detection of Lp(a), CHR and Lp(a) CHR had predictive value for MACE in AMI patients during hospitalization, and the combined detection value was higher. Conclusion: Lp(a) and CHR are independent risk factors for MACE in AMI patients during hospitalization. Combined detection of Lp(a) and CHR is helpful to evaluate the short-term prognosis of AMI patients.
BAO Ruina
,
WANG Yingnan
,
ZHAO Ruiping
. The predictive value of Lp(a) and CHR for short-term prognosis in patients with acute myocardial infarction[J]. Journal of Baotou Medical College, 2024
, 40(4)
: 42
-46
.
DOI: 10.16833/j.cnki.jbmc.2024.04.008
[1] The Writing Committee of the Report on Cardiovascular Health Diseases in China.《中国心血管健康与疾病报告2021》要点解读[J].中国心血管杂志,2022,27(4):305-318.
[2] Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction[J].Lancet,2017,389(10065):197-210.
[3] 廖付军,鲍海龙,谢登海,等. 冠心病患者胆红素血脂综合指数与冠状动脉狭窄程度的相关性[J].贵州医科大学学报,2021,46(8): 925-930.
[4] Whayne TF.Non-traditional cardiovascular risk markers in the era of established major risk factors and multiple guidelines[J].Curr Vasc Pharmacol,2019,17(3):270-277.
[5] Wilson DP,Jacobson TA,Jones PH,et al. Use of Lipoprotein(a)in clinical practice:a biomarker whose time has come.A scientific statement from the National Lipid Association[J].JClin Lipidol, 2019,13(3):374-392.
[6] Jang AY, Han SH, Sohn IS, et al. Lipoprotein(a) and cardiovascular diseases - revisited[J].CircJ, 2020,84(6):867-874.
[7] 徐娜. 血清脂蛋白(a)与冠心病患者冠脉严重程度及远期预后的相关性研究[D].北京:北京协和医学院,2020.
[8] Avan A, Tavakoly Sany SB, Ghayour-Mobarhan M, et al. Serum C-reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice[J].J Cell Physiol,2018,233(11):8508-8525.
[9] RosensonRS, Brewer HB, Barter PJ, et al. HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology[J]. Nat RevCardiol,2018,15(1):9-19.
[10] 屠思佳,袁红,章慧慧,等.MHR联合Lp(a)对急性心肌梗死患者PCI治疗后短期预后的预测价值[J].心电与循环,2022,41(5):445-449.
[11] Sumarjaya ID, Nagha IB, Lestar AAW. High lipoprotein(a) levels as a predictor of major adverse cardiovascular events in hospitalized-Acute myocardial infarction patients[J].VascHealth Risk Manag,2020,16:125-132.
[12] 薛雅芝,曾晓容,林子祥,等.C反应蛋白高密度脂蛋白胆固醇比值、中性粒细胞淋巴细胞比值对冠心病的预测价值研究[J].中国全科医学,2020,23(25):3194-3199,3206.
[13] 朱泽阳,黄维,王旭颖,等.C反应蛋白与高密度脂蛋白胆固醇比值预测缺血性脑卒中患者颈动脉斑块易损性的诊断价值研究[J].中风与神经疾病杂志,2021,38(8):707-710.
[14] Chen Z, Jiang C, Qu H, et al. Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention[J].Arch Med Sci,2019,15(6):1375-1380.
[15] Takahashi D, Wada H, OGgita M, et al. Impact of lipoprotein(a) as a residual risk factor in long-term cardiovascular outcomes in patients with acutecoronary syndrome treated with statins[J].Am J Cardiol, 2022,168:11-16.
